PTEN and neoplasm: Despite PD-L1 expression in tumor cells ranging from 61% to 88%, clinical trials such as CheckMate-143 have failed to show significant survival benefits.370 This limited efficacy is linked to poor BBB penetration, low tumor-infiltrating lymphocyte levels, and PTEN mutations, which are prevalent in nonresponders.